Tag Archives: Jason Mccarthy

ADMA Biologics (ADMA) Receives a Buy from Maxim Group

Maxim Group analyst Jason McCarthy maintained a Buy rating on ADMA Biologics (NASDAQ: ADMA) today and set a price target of $12. The company’s shares closed yesterday at $5.29. McCarthy noted: “ADMA announced that FDA has accepted the BLA resubmission

Mesoblast Ltd (MESO) Gets a Buy Rating from Maxim Group

Maxim Group analyst Jason McCarthy maintained a Buy rating on Mesoblast Ltd (NASDAQ: MESO) today and set a price target of $16. The company’s shares opened today at $7.01. McCarthy observed: “Mesoblast announced the completion of the strategic partnership agreement

Maxim Group Keeps a Buy Rating on ADMA Biologics (ADMA)

In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on ADMA Biologics (NASDAQ: ADMA), with a price target of $12. The company’s shares opened today at $5.61. McCarthy wrote: “ADMA provided an update on the

Maxim Group Keeps Their Buy Rating on Atossa Genetics (ATOS)

Maxim Group analyst Jason McCarthy maintained a Buy rating on Atossa Genetics (NASDAQ: ATOS) today and set a price target of $7. The company’s shares opened today at $1.65, close to its 52-week low of $1.41. McCarthy observed: “Atossa Genetics

Viking Therapeutics (VKTX) Received its Third Buy in a Row

After H.C. Wainwright and SunTrust Robinson gave Viking Therapeutics (NASDAQ: VKTX) a Buy rating last month, the company received another Buy, this time from Maxim Group. Analyst Jason McCarthy maintained a Buy rating on Viking Therapeutics today and set a

Maxim Group Maintains a Hold Rating on Cancer Genetics (CGIX)

In a report released today, Jason McCarthy from Maxim Group maintained a Hold rating on Cancer Genetics (NASDAQ: CGIX). The company’s shares opened today at $0.98, close to its 52-week low of $0.82. McCarthy observed: “Cancer Genetics (CGI) announced a